[1]
O’Brien, S. 2009. Minimal residual disease elimination by consolidation therapy with alemtuzumab. Hematology Meeting Reports (formerly Haematologica Reports). 1, 2 (May 2009). DOI:https://doi.org/10.4081/hmr.v1i2.227.